Hmsh2 and hmlh1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: Correlation with patient survival and response to adjuvant chemotherapy treatment

International Journal of Biological Markers

Volumn 27, Issue 4, 2012, Pages

  Vageli, Dimitra P ^a   Zaravinos, Apostolos ^a   Daniil, Zoe ^a   Dahabreh, Jubrail ^a   Doukas, Sotirios G ^a   Spandidos, Demetrios A ^b   Gourgoulianis, Konstantinos I ^c   Koukoulis, George K ^d  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d ATHENS MEDICAL CENTER   (Greece)

Author keywords

Chemotherapy; Hmlh1; Hmsh2; Mmr; Nsclc; Survival

Indexed keywords

CISPLATIN; MESSENGER RNA; PROTEIN MLH1; PROTEIN MSH2;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DEATH; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MISMATCH REPAIR; PHENOTYPE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DNA MISMATCH REPAIR; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PHENOTYPE; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84872851736     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/JBM.2012.9420     Document Type: Article

References (20)

1. van der Klift H, Wijnen J, Wagner A, et al. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary non-polyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 2005; 44: 123-38.
2. Montazer Haghighi M, Radpour R, Aghajani K, Zali N, Molaei M, Zali MR. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary non-polyposis colorectal cancer. Int J Colorectal Dis 2009; 24: 885-93.
3. Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090-5.
4. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17: 2413-7.
5. Sasaki S, Nakamura Y. Mutation of the mismatch repair genes for carcinogenesis of sporadic colorectal cancers with RER-positive phenotype. Nippon Rinsho 1996; 54: 1008-13.
6. Burger M, Den Zinger S, Hammerschmied CG, et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med 2006; 84: 833-41.
7. Kassem HS, Varley JM, Hamam SM, Margison GP. Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer. Br J Cancer 2001; 84: 321-8.
8. Leach FS, Hsieh JT, Molberg K, et al. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy. Cancer 2000; 88: 2333-41.
9. Vageli D, Daniil Z, Dahabreh J, et al. Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer 2009; 64: 282-8.
10. Wistuba II. Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 2007; 7: 3-14.
11. Herbst RS, Heymach JV, Lippman SMN. Lung cancer. N Engl J Med 2008; 359: 1367-80.
12. Cooper WA, Kohonen-Corish MR, Chan C, et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 2008; 52: 613-22.
13. Ollila S, Dermadi Bebek D, Jiricny J, Nyström M. Mechanisms of pathogenicity in human MSH2 missense mutants. Hum Mutat 2008; 29: 1355-63.
14. Kijas AW, Studamire B, Alani E. Msh2 separation of function mutations confers defects in the initiation steps of mismatch repair. J Mol Biol 2003; 331: 123-38.
15. Amin NS, Nguyen MN, Oh S, Kolodner RD. Exo1- dependent mutator mutations: model system for studying functional interactions in mismatch repair. Mol Cell Biol 2001; 21: 5142-55.
16. Rosell R, Taron M, Massuti B, et al. Predicting response to chemotherapy with early-stage lung cancer. Cancer J 2011; 17: 49-56.
17. Drotschmann K, Topping RP, Clodfelter JE, Salsbury FR. Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair (Amst) 2004; 3: 729-42.
18. Salsbury FR Jr, Clodfelter JE, Gentry MB, Hollis T, Scarpinato KD. The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response. Nucleic Acids Res 2006; 34: 2173-85.
19. Cohn DE, Frankel WL, Resnick KE, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 2006; 108: 1208-15.
20. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-67.